Loading
Latest filing published 06 Jul 2021 for MEI Pharma, Inc., €62k.
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
All filings by David M. Urso on record concern Lite Strategy, Inc., in the capacity of chief executive. Between 6 August 2018 and 2 July 2021, the trades on record add up to 4 filings.
The open-market record consists of 1 sale worth €29k, with no purchase. Besides market trades, the filings include 3 share grants.
Most recently, on 6 July 2021, the filings show a share grant worth €62k in Lite Strategy, Inc. Filings reach the SEC (Form 4) feed a median of 3 days after the trade. Section 16 rules allow two business days to file each Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
1 of 1 declaration